CPIX - Cumberland Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Cumberland Pharmaceuticals Inc.

2525 West End Avenue
Suite 950
Nashville, TN 37203
United States
615-255-0068
http://www.cumberlandpharma.com

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees80

Key Executives

NameTitlePayExercisedYear Born
Mr. A. J. KazimiFounder, Chairman, Pres & CEO807.45kN/A1958
Mr. Michael P. BonnerCFO and Sr. Director of Fin. & Accounting225kN/A1977
Mr. Leo B. PavlivExec. VP of Operations & Chief Devel. Officer472.45kN/A1961
Mr. James Lowrance HermanSr. VP of National Accounts & Chief Compliance Officer295kN/A1955
Mr. Martin E. CearnalExec. VP of Marketing & Sales, Chief Commercial Officer and Director380kN/A1945
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections. The company's Phase II product candidates includes Hepatoren injection for the treatment of critically ill patients suffering from liver and kidney failure; Boxaban oral capsules for the treatment of asthma patients; Vasculan oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as severe disabling psoriasis. The company markets and sells its products through sales representatives and district managers. Cumberland Pharmaceuticals Inc. has a strategic alliance with Clinigen Group plc and Nordic Group B.V. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Corporate Governance

Cumberland Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.